Livanova (LIVN) PT Raised to $81 at Needham

Needham analyst Mike Matson raised the price target on Livanova (NASDAQ: LIVN) to $81.00 (from $64.00) while maintaining a Buy rating.

The analyst comments "LIVN's 4Q25 revenue and EPS beat consensus. LIVN provided 2026 organic revenue and EPS guidance that was above consensus. Organic revenue growth slowed to 9.5% in 4Q25 from 12.5% in 3Q25. Both LIVN's Cardiopulmonary and Neuromodulation businesses beat consensus and compared to 3Q25, Cardiopulmonary saw slower growth while Neuromodulation saw stronger growth. Gross margin was down 20 bps Y/Y and operating margin was up 40 bps Y/Y. With LIVN likely to benefit from improved epilepsy reimbursement and nearing FDA approval of its obstructive sleep apnea (OSA) device, we reiterate our Buy rating. We raise our price target to $81 from $64 as we shift to valuing LIVN on our 2027E EPS."

You May Also Be Interested In

• Morgan Stanley Starts Sampo Oyj (SAMPO:FH) (SAXPY) at Equalweight
• Berenberg Starts Alm Brand A/S (ALMB:DC) at Hold
• JPMorgan Downgrades Pearson PLC (PSON:LN) (PSO) to Neutral